tirzepatide discontinuation Meta-analysis results for of by adverse Potential Maintenance Off-Ramp Showing Promise

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Appetite is significantly suppressed

Work with your healthcare provider to make a good plan for monitoring your blood sugar

Nausea Diarrhoea Vomiting Abdominal pain Constipation They are most common when first starting tirzepatide but decrease over time in most patients

Brand-name (Mounjaro and Zepbound) Mounjaro (for type 2 diabetes) and Zepbound (for weight management) are the brand-name versions of tirzepatide manufactured by Eli Lilly

Cardiovascular Diabetology, 2 0(1), 225